Program

Oral Sessions

Day 4, May 18（Fri.）　16:05-16:25　Room A (OrBit Hall)

4A-O2-P-1605　　PDF

Proteogenomics for sarcoma research: International Cancer Proteogenomics Consortium (ICPC)

(¹NCCRC, ²IUHW)
^oTadashi Kondo¹, Enu Hattiru¹, Kumiko Shiozawa¹, Masayha Ono¹, Mari Masuda¹, Teshi Yamada²

Sarcomas are malignant mesenchymal tumors, arising from almost everywhere in human body. Sarcomas are rare cancers, accounting for less than 1% of all malignancies. We have conducted the problem-oriented cancer research with proteomics modalities since 2002. Using clinical materials such as tumor tissues and plasma samples, we identified many intriguing proteins, and developed diagnostic, prognostic or predictive biomarkers.
We realized an inherent problem of cancer proteomics using mass spectrometry. Although mass spectrometry detects the signals from peptides with aberrant amino acid sequence, we cannot identify them, and only proteins with sequences recorded in the public databases are studied in cancer proteomics. With this notion, we launched a proteogenomics project. In the project, we obtain both genome and mass spectrometry data from identical tumor tissue samples. The individual genome data are translated and integrated into proteome database for mass spectrometric protein identification. To conduct the proteogenomics analysis, we created a unique software, “Mutated Nucleotide and Amino-acid sequence Generator (MuNaGe)”. MuNaGe integrates multi-omics data, generating patient-specific proteomic aberrations.
We join to the International Cancer Proteogenomics Consortium (ICPC). Considering a limited number of cases and samples, we do need such a world-wide activity for rare cancers.